HGH 191AA / Recombinant Human GH (10 IU Vial) Dosage Protocol
HGH 191AA is recombinant human growth hormone — the full 191-amino acid somatotropin sequence identical to endogenous pituitary GH. Unlike secretagogues (GHRH analogs, GHRPs) which stimulate the pituitary to produce its own GH, HGH directly provides exogenous growth hormone. Dosing is in IU (International Units), not mcg.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous (preferred) or IM | Frequency: Once daily or split twice daily
| Application | Daily Dose | U-100 Units | Volume | Notes |
|---|---|---|---|---|
| Anti-aging / recovery | 1–2 IU/day | 10–20 units | 0.10–0.20 mL | Conservative; long-term sustainable |
| Body composition | 2–4 IU/day | 20–40 units | 0.20–0.40 mL | Standard research range |
| Split protocol | 2 IU AM + 2 IU post-workout | 20 units each | 0.20 mL each | Mimics natural biphasic release |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the vial; avoid foaming.
- Gently swirl until dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.
Supplies Planning
| Item | 8 Weeks (2 IU/day) | 12 Weeks (3 IU/day) |
|---|---|---|
| HGH vials (10 IU each) | 12 vials | 26 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 2 × 10 mL | 3 × 10 mL |
| Alcohol swabs | 1–2 × 100-pack | 2 × 100-pack |
Mechanism of Action
Recombinant human GH 191AA is biosynthetically identical to pituitary-derived GH: a 191-amino acid single-chain polypeptide with two intramolecular disulfide bonds (Cys-53/Cys-165 and Cys-182/Cys-189). Unlike secretagogues, it bypasses the hypothalamic-pituitary axis entirely — providing exogenous GH directly to peripheral tissues.
Its primary actions are mediated both directly (through GH receptors on tissues) and indirectly (through IGF-1 produced in the liver in response to GH stimulation). Direct GH receptor activation promotes lipolysis, protein synthesis, and anti-catabolism. IGF-1 production mediates most of the anabolic, muscle-building effects. Unlike GHRH/GHRP protocols which preserve IGF-1 negative feedback, exogenous HGH continuously elevates both GH and IGF-1 — which is why cycle management is critical.
Research Findings & Safety Profile
- FDA approved (prescription) for GH deficiency, Prader-Willi syndrome, Turner syndrome, AIDS wasting, and short bowel syndrome.
- Research-grade HGH is not the same as pharmaceutical-grade — purity and sterility standards vary significantly.
- Exogenous HGH suppresses the HPG axis via somatostatin feedback — longer cycles can reduce endogenous GH production.
- Possible effects: water retention (carpal tunnel symptoms), joint pain/stiffness, insulin resistance, headaches, acromegalic features at high doses.
- Glucose metabolism: HGH is anti-insulin — elevated fasting glucose and insulin resistance are dose-dependent effects at supraphysiological levels.
- WADA prohibited. Detectable by GH serum isoform differential assay (GH-2000 test) for days to weeks.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months | Dry, dark conditions |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days | Avoid freeze-thaw; protect from light |